文献速递白血病

微环境CXCL12缺失通过降低p38 MAPK信号增强Flt3-ITD急性髓系白血病干细胞对治疗的反应

Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
PubMed 文献 · Leukemia · 2022-12-22

本研究利用Flt3-ITD合并Tet2缺失的AML遗传小鼠模型,发现白血病干细胞富集于原始ST-HSC群体且CXCR4表达增加,微环境CXCL12缺失可增强Flt3-TKI联合化疗对AML细胞及干细胞的靶向清除,p38抑制可减少基质细胞依赖与非依赖的白血病干细胞维持并增强治疗敏感性。

要点

  • Flt3-ITD AML干细胞富集于原始ST-HSC群体,其CXCR4表达增加。
  • 微环境CXCL12缺失增强Flt3-TKI联合化疗对AML细胞及干细胞的靶向。
  • p38抑制联合化疗加TKI对Flt3-ITD AML干细胞的清除优于CXCL12缺失。

核心结论

  • 研究支持CXCL12和p38信号在微环境对AML干细胞的保护中发挥作用,并为抑制p38信号以增强Flt3-ITD AML靶向提供依据。

研究设计与样本

  • 利用Flt3-ITD合并Tet2缺失的AML遗传小鼠模型进行实验研究。

主要发现

  • FLT3-ITD AML白血病干细胞富集于原始ST-HSC群体,且CXCR4表达增加。
  • Flt3-ITD AML骨髓中CXCL12丰富的网状(CAR)细胞增多。
  • 微环境CXCL12缺失增强Flt3-TKI联合化疗对AML细胞的靶向,包括增强对白血病干细胞的靶向。
  • 治疗和CXCL12缺失均部分降低AML细胞中p38信号,CXCL12缺失小鼠治疗后p38信号进一步降低。
  • p38抑制减少MSC对鼠源和人源Flt3-ITD AML干细胞的CXCL12依赖性和非依赖性维持,并增强其对治疗的敏感性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fms-like tyrosine kinase 3 (Flt3) tyrosine kinase inhibitors (Flt3-TKI) have improved outcomes for patients with Flt3-mutated acute myeloid leukemia (AML) but are limited by resistance and relapse, indicating persistence of leukemia stem cells (LSC). Here utilizing a Flt3-internal tandem duplication (Flt3-ITD) and Tet2-deleted AML genetic mouse model we determined that FLT3-ITD AML LSC were enriched within the primitive ST-HSC population. FLT3-ITD LSC showed increased expression of the CXCL12 receptor CXCR4. CXCL12-abundant reticular (CAR) cells were increased in Flt3-ITD AML marrow. CXCL12 deletion from the microenvironment enhanced targeting of AML cells by Flt3-TKI plus chemotherapy treatment, including enhanced LSC targeting. Both treatment and CXCL12 deletion partially reduced p38 mitogen-activated protein kinase (p38) signaling in AML cells and further reduction was seen after treatment in CXCL12 deleted mice. p38 inhibition reduced CXCL12-dependent and -independent maintenance of both murine and human Flt3-ITD AML LSC by MSC and enhanced their sensitivity to treatment. p38 inhibition in combination with chemotherapy plus TKI treatment leads to greater depletion of Flt3-ITD AML LSC compared with CXCL12 deletion. Our studies support roles for CXCL12 and p38 signaling in microenvironmental protection of AML LSC and provide a rationale for inhibiting p38 signaling to enhance Flt3-ITD AML targeting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Anderson NR, Sheth V, Li H, et al. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. Leukemia. 2022. PMID: 36550214. doi:10.1038/s41375-022-01798-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。